Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Delirium 2Vomiting 1Urinary Tract Infections 1Staphylococcal Infections 1Spasm 1Sleep Initiation and Maintenance Disorders 1Sepsis 1Seizures 1Schizophrenia, Treatment-Resistant 1Schizophrenia 1Retinitis 1Renal Insufficiency, Chronic 1Pulmonary Arterial Hypertension 1Pneumonia 1Pain 1Neutropenia 1Nausea 1Migraine Disorders 1Menorrhagia 1Meningitis, Bacterial 1Meningitis 1Intraabdominal Infections 1Influenza, Human 1Inflammation 1Infections 1Hypokalemia 1Hypertension 1Hyperaldosteronism 1Herpes Simplex 1Hemophilia A 1

Interventions

Trastuzumab 350Paclitaxel 334Cyclophosphamide 315Docetaxel 291Capecitabine 181Doxorubicin 180Letrozole 166Tamoxifen 145Bevacizumab 124Fulvestrant 118Carboplatin 118exemestane 111Lapatinib 111Anastrozole 111Radiotherapy 105Epirubicin 104Gemcitabine 97palbociclib 84Exercise 78Vinorelbine 77Fluorouracil 77Surveys and Questionnaires 71pertuzumab 67Filgrastim 64Albumin-Bound Paclitaxel 64eribulin 55Magnetic Resonance Spectroscopy 55Everolimus 52Blood Specimen Collection 51Zoledronic Acid 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Breast Neoplasms × Haloperidol × Clear all
NCT01298193 2023-03-07

Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.

Spanish Breast Cancer Research Group

Phase 4 Completed
212 enrolled 19 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡